stockrowAtea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
- EPS
- +6.82%
- Free cash flow
- +85.5%
Quarter to June 2026, against a year earlier
Follow AVIR
Alert me
Atea Pharmaceuticals, Inc. (AVIR) EV/Sales
As of 6 November 2026, Atea Pharmaceuticals, Inc. (AVIR) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −1.1× (March 2023) to 13.7× (October 2021); the current reading is higher than 90% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −0.1× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | −0.1× | — |
| Sep 2021 | 9.9× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. | 0.4× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 1.8× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 9.0× |
| SRZN Surrozen, Inc. compare | 22.7× |
| IRD Opus Genetics, Inc. compare | 35.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)